Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wolff

Showing results (691-700 of 831) with videos related to

Pageof 84
Sort By:
Molecular Psychiatry|May 29, 2021
Microglia-specific knock-down of Bmal1 improves memory and protects mice from high fat diet-induced obesityXiao-Lan Wang, Sander Kooijman, Yuanqing Gao, et al.
The Oncologist|January 30, 2013
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experienceOtto Metzger-Filho, Evandro de Azambuja, Ian Bradbury, et al.
Cancer Research|April 17, 2014
Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancerMary Jo Fackler, Zoila Lopez Bujanda, Christopher Umbricht, et al.
JAMA Oncology|December 14, 2023
Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical TrialBrian D Lehmann, Vandana G Abramson, E Claire Dees, et al.
Archives of Pathology & Laboratory Medicine|May 31, 2018
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused UpdateAntonio C Wolff, M Elizabeth Hale Hammond, Kimberly H Allison, et al.
JCO Oncology Practice|September 21, 2023
Feasibility of Symptom Monitoring During the First Year of Endocrine Therapy for Early Breast Cancer Using Patient-Reported Outcomes Collected via Smartphone AppKaren Lisa Smith, Hua-Ling Tsai, David Lim, et al.
Future Oncology (London, England)|October 6, 2025
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial)Maeve A Hennessy, Constantine Gatsonis, Heather Jacene, et al.
Breast Cancer Research and Treatment|May 13, 2018
A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trialCesar A Santa-Maria, Aditya Bardia, Amanda L Blackford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2018
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused UpdateAntonio C Wolff, M Elizabeth Hale Hammond, Kimberly H Allison, et al.
The New England Journal of Medicine|June 7, 2016
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 YearsPaul E Goss, James N Ingle, Kathleen I Pritchard, et al.
Pageof 84

Showing results (691-700 of 831) with videos related to

Sort By:
Pageof 84
Molecular Psychiatry|May 29, 2021
Microglia-specific knock-down of Bmal1 improves memory and protects mice from high fat diet-induced obesityXiao-Lan Wang, Sander Kooijman, Yuanqing Gao, et al.
The Oncologist|January 30, 2013
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experienceOtto Metzger-Filho, Evandro de Azambuja, Ian Bradbury, et al.
Cancer Research|April 17, 2014
Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancerMary Jo Fackler, Zoila Lopez Bujanda, Christopher Umbricht, et al.
JAMA Oncology|December 14, 2023
Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical TrialBrian D Lehmann, Vandana G Abramson, E Claire Dees, et al.
Archives of Pathology & Laboratory Medicine|May 31, 2018
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused UpdateAntonio C Wolff, M Elizabeth Hale Hammond, Kimberly H Allison, et al.
JCO Oncology Practice|September 21, 2023
Feasibility of Symptom Monitoring During the First Year of Endocrine Therapy for Early Breast Cancer Using Patient-Reported Outcomes Collected via Smartphone AppKaren Lisa Smith, Hua-Ling Tsai, David Lim, et al.
Future Oncology (London, England)|October 6, 2025
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial)Maeve A Hennessy, Constantine Gatsonis, Heather Jacene, et al.
Breast Cancer Research and Treatment|May 13, 2018
A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trialCesar A Santa-Maria, Aditya Bardia, Amanda L Blackford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2018
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused UpdateAntonio C Wolff, M Elizabeth Hale Hammond, Kimberly H Allison, et al.
The New England Journal of Medicine|June 7, 2016
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 YearsPaul E Goss, James N Ingle, Kathleen I Pritchard, et al.
Pageof 84